Literature DB >> 22987091

Gemtuzumab ozogamicin: time to resurrect?

Farhad Ravandi1, Elihu H Estey, Frederick R Appelbaum, Francesco Lo-Coco, Charles A Schiffer, Richard A Larson, Alan K Burnett, Hagop M Kantarjian.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22987091      PMCID： PMC4874205          DOI： 10.1200/JCO.2012.43.0132

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  16 in total

1.  Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.

Authors:  P F Bross; J Beitz; G Chen; X H Chen; E Duffy; L Kieffer; S Roy; R Sridhara; A Rahman; G Williams; R Pazdur
Journal:  Clin Cancer Res       Date:  2001-06       Impact factor: 12.531

2.  Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

Authors:  Alan K Burnett; Robert K Hills; Donald Milligan; Lars Kjeldsen; Jonathan Kell; Nigel H Russell; John A L Yin; Ann Hunter; Anthony H Goldstone; Keith Wheatley
Journal:  J Clin Oncol       Date:  2010-12-20       Impact factor: 44.544

3.  Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia.

Authors:  Elihu H Estey; Francis J Giles; Miloslav Beran; Susan O'Brien; Sherry A Pierce; Stefan H Faderl; Jorge E Cortes; Hagop M Kantarjian
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

4.  Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy.

Authors:  Pankaj Rajvanshi; Howard M Shulman; Eric L Sievers; George B McDonald
Journal:  Blood       Date:  2002-04-01       Impact factor: 22.113

5.  Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia.

Authors:  Massimo Breccia; Giuseppe Cimino; Daniela Diverio; Fabiana Gentilini; Franco Mandelli; Francesco Lo Coco
Journal:  Haematologica       Date:  2007-09       Impact factor: 9.941

6.  Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.

Authors:  Farhad Ravandi; Eli Estey; Dan Jones; Stefan Faderl; Susan O'Brien; Jackie Fiorentino; Sherry Pierce; Deborah Blamble; Zeev Estrov; William Wierda; Alessandra Ferrajoli; Srdan Verstovsek; Guillermo Garcia-Manero; Jorge Cortes; Hagop Kantarjian
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

7.  Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation.

Authors:  Martha Wadleigh; Paul G Richardson; David Zahrieh; Stephanie J Lee; Corey Cutler; Vincent Ho; Edwin P Alyea; Joseph H Antin; Richard M Stone; Robert J Soiffer; Daniel J DeAngelo
Journal:  Blood       Date:  2003-05-08       Impact factor: 22.113

8.  High-dose daunorubicin in older patients with acute myeloid leukemia.

Authors:  Bob Löwenberg; Gert J Ossenkoppele; Wim van Putten; Harry C Schouten; Carlos Graux; Augustin Ferrant; Pieter Sonneveld; Johan Maertens; Mojca Jongen-Lavrencic; Marie von Lilienfeld-Toal; Bart J Biemond; Edo Vellenga; Marinus van Marwijk Kooy; Leo F Verdonck; Joachim Beck; Hartmut Döhner; Alois Gratwohl; Thomas Pabst; Gregor Verhoef
Journal:  N Engl J Med       Date:  2009-09-24       Impact factor: 91.245

9.  Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group.

Authors:  Mark R Litzow; Megan Othus; Larry D Cripe; Steven D Gore; Hillard M Lazarus; Sandra J Lee; John M Bennett; Elisabeth M Paietta; Gordon W Dewald; Jacob M Rowe; Martin S Tallman
Journal:  Br J Haematol       Date:  2009-10-05       Impact factor: 6.998

10.  Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.

Authors:  Alan K Burnett; Nigel H Russell; Robert K Hills; Jonathan Kell; Sylvie Freeman; Lars Kjeldsen; Ann E Hunter; John Yin; Charles F Craddock; Inge Hoegh Dufva; Keith Wheatley; Donald Milligan
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544
View more
  37 in total

Review 1.  Molecular therapy for acute myeloid leukaemia.

Authors:  Catherine C Coombs; Martin S Tallman; Ross L Levine
Journal:  Nat Rev Clin Oncol       Date:  2015-12-01       Impact factor: 66.675

Review 2.  Novel agents for the treatment of childhood acute leukemia.

Authors:  Colleen E Annesley; Patrick Brown
Journal:  Ther Adv Hematol       Date:  2015-04

3.  Acute myeloid leukemia therapy and the chosen people.

Authors:  E Estey; R P Gale
Journal:  Leukemia       Date:  2016-11-11       Impact factor: 11.528

Review 4.  Siglec-mediated regulation of immune cell function in disease.

Authors:  Matthew S Macauley; Paul R Crocker; James C Paulson
Journal:  Nat Rev Immunol       Date:  2014-09-19       Impact factor: 53.106

5.  Vorinostat downregulates CD30 and decreases brentuximab vedotin efficacy in human lymphocytes.

Authors:  Zainul S Hasanali; Elliot M Epner; David J Feith; Thomas P Loughran; Clare E Sample
Journal:  Mol Cancer Ther       Date:  2014-10-15       Impact factor: 6.261

6.  Extending the market exclusivity of therapeutic antibodies through dosage patents.

Authors:  Ulrich Storz
Journal:  MAbs       Date:  2016-04-26       Impact factor: 5.857

7.  Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML.

Authors:  Fabiana Perna; Samuel H Berman; Rajesh K Soni; Jorge Mansilla-Soto; Justin Eyquem; Mohamad Hamieh; Ronald C Hendrickson; Cameron W Brennan; Michel Sadelain
Journal:  Cancer Cell       Date:  2017-10-09       Impact factor: 31.743

8.  Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.

Authors:  Yasmin Abaza; Hagop Kantarjian; Guillermo Garcia-Manero; Elihu Estey; Gautam Borthakur; Elias Jabbour; Stefan Faderl; Susan O'Brien; William Wierda; Sherry Pierce; Mark Brandt; Deborah McCue; Rajyalakshmi Luthra; Keyur Patel; Steven Kornblau; Tapan Kadia; Naval Daver; Courtney DiNardo; Nitin Jain; Srdan Verstovsek; Alessandra Ferrajoli; Michael Andreeff; Marina Konopleva; Zeev Estrov; Maria Foudray; David McCue; Jorge Cortes; Farhad Ravandi
Journal:  Blood       Date:  2016-12-21       Impact factor: 22.113

9.  A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia.

Authors:  Sucha Nand; Megan Othus; John E Godwin; Cheryl L Willman; Thomas H Norwood; Dianna S Howard; Steven E Coutre; Harry P Erba; Frederick R Appelbaum
Journal:  Blood       Date:  2013-10-03       Impact factor: 22.113

10.  A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.

Authors:  Stephen H Petersdorf; Kenneth J Kopecky; Marilyn Slovak; Cheryl Willman; Thomas Nevill; Joseph Brandwein; Richard A Larson; Harry P Erba; Patrick J Stiff; Robert K Stuart; Roland B Walter; Martin S Tallman; Leif Stenke; Frederick R Appelbaum
Journal:  Blood       Date:  2013-04-16       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.